DRUG DOSAGE AND ADMINISTRATION Ajmaline 1 mg/kg over 5
... resuscitation. Particular caution should be exercised in patients with a pre‐existing atrial or ventricular conduction (or both) disturbance (e.g. suspected cases of Lev or Lenègre disease) or in the presence of wide QRS, wide P waves, or prolonged PR intervals (i.e. in ...
... resuscitation. Particular caution should be exercised in patients with a pre‐existing atrial or ventricular conduction (or both) disturbance (e.g. suspected cases of Lev or Lenègre disease) or in the presence of wide QRS, wide P waves, or prolonged PR intervals (i.e. in ...
Congestive Heart Failure
... Has reduced clinical indecision from 43-11% Median BNP levels in NYHA classes I, II, III, and IV were 244, 389, 640, and 817 pg/ml, respectively. Values of 50 pg/ml or less had a negative predictive value of 96% Maisel, A et al. Rapid Measurement of B-Type Natriuretic Peptide in the Emergency ...
... Has reduced clinical indecision from 43-11% Median BNP levels in NYHA classes I, II, III, and IV were 244, 389, 640, and 817 pg/ml, respectively. Values of 50 pg/ml or less had a negative predictive value of 96% Maisel, A et al. Rapid Measurement of B-Type Natriuretic Peptide in the Emergency ...
The Cardiac Cycle - The Grange School Blogs
... Pressure changes in the heart • The diagram shows the pressure changes during a cardiac cycle on the left side of the heart • Note that the maximal pressure in the left ventricle is far higher than in the atrium • This is because the ventricle has to work hard to pump blood to all parts of the body ...
... Pressure changes in the heart • The diagram shows the pressure changes during a cardiac cycle on the left side of the heart • Note that the maximal pressure in the left ventricle is far higher than in the atrium • This is because the ventricle has to work hard to pump blood to all parts of the body ...
心脏瓣膜病
... The Medtronic InSync device is indicated for the reduction of the symptoms of moderate to severe heart failure (NYHA Functional Class III or IV) in those patients who remain symptomatic despite stable, optimal medical therapy, and have a left ventricular ejection fraction less than or equal to 35% a ...
... The Medtronic InSync device is indicated for the reduction of the symptoms of moderate to severe heart failure (NYHA Functional Class III or IV) in those patients who remain symptomatic despite stable, optimal medical therapy, and have a left ventricular ejection fraction less than or equal to 35% a ...
Heart - KingsfieldBiology
... ventricles. important delay of about 0.1s. Ventricles contract shortly after the atria, from the bottom up, squeezing blood upwards into the arteries. The blood can't go into the atria because of the ...
... ventricles. important delay of about 0.1s. Ventricles contract shortly after the atria, from the bottom up, squeezing blood upwards into the arteries. The blood can't go into the atria because of the ...
Version 1
... In patients undergoing general anaesthesia the anaesthetist must be aware of beta-blockade. If it is thought necessary to withdraw beta-blocker therapy before surgery, this should be done gradually and completed about 48 hours before anaesthesia. In bronchial asthma or other chronic obstructive pul ...
... In patients undergoing general anaesthesia the anaesthetist must be aware of beta-blockade. If it is thought necessary to withdraw beta-blocker therapy before surgery, this should be done gradually and completed about 48 hours before anaesthesia. In bronchial asthma or other chronic obstructive pul ...
inhibition of pyruvate dehydrogenase kinase decreases the severity
... accompanying heart failure are complex, and are partly dependent on the stage/severity of the syndrome. However, an elevation in glycolytic rates in relation to glucose oxidation in the failing heart is a consistent finding. We showed an increased uncoupling of glycolysis from glucose oxidation, acc ...
... accompanying heart failure are complex, and are partly dependent on the stage/severity of the syndrome. However, an elevation in glycolytic rates in relation to glucose oxidation in the failing heart is a consistent finding. We showed an increased uncoupling of glycolysis from glucose oxidation, acc ...
Version 1
... blockade. In patients undergoing general anaesthesia the anaesthetist must be aware of beta-blockade. If it is thought necessary to withdraw beta-blocker therapy before surgery, this should be done gradually and completed about 48 hours before anaesthesia. In bronchial asthma or other chronic obstru ...
... blockade. In patients undergoing general anaesthesia the anaesthetist must be aware of beta-blockade. If it is thought necessary to withdraw beta-blocker therapy before surgery, this should be done gradually and completed about 48 hours before anaesthesia. In bronchial asthma or other chronic obstru ...
BozkurtACCF_AHAHFGuidelineNew2013
... duration of ≥ 150 ms. In this guideline, which is harmonized with the 2012 ACCF/AHA/HRS focused update guidelines for device-based therapy,6 Class I indication is expanded to patients with milder symptoms (NYHA Class II HF) but with LBBB and QRS ≥150 msec. The patients with LBBB, but QRS duration o ...
... duration of ≥ 150 ms. In this guideline, which is harmonized with the 2012 ACCF/AHA/HRS focused update guidelines for device-based therapy,6 Class I indication is expanded to patients with milder symptoms (NYHA Class II HF) but with LBBB and QRS ≥150 msec. The patients with LBBB, but QRS duration o ...
Reduced LVEF with Symptoms
... • They also blunt the usual angiogensin II-mediated increase in adrenaline and aldesterone seen in HF. • These agents show a significant decrease in the mortality and morbidity. • May be considered as a single-agent therapy in patients who have mild dyspnea on excursion, and do not have signs of vol ...
... • They also blunt the usual angiogensin II-mediated increase in adrenaline and aldesterone seen in HF. • These agents show a significant decrease in the mortality and morbidity. • May be considered as a single-agent therapy in patients who have mild dyspnea on excursion, and do not have signs of vol ...
Perioperative management of a patient with left ventricular failure
... Surgical management of heart failure is the new dimension that has now been added in the management of end-stage heart failure. The spectrum of surgical procedures range from coronary artery bypass grafting to heart transplantation. However, the availability of donor hearts far outnumbers the number ...
... Surgical management of heart failure is the new dimension that has now been added in the management of end-stage heart failure. The spectrum of surgical procedures range from coronary artery bypass grafting to heart transplantation. However, the availability of donor hearts far outnumbers the number ...
A1982PS35000001
... 400,000 lives annually in the US. If they are to be saved, the victims need to be identified prior to the fatal event. The presenceof certain types of ventricular extrasystoles exposed by monitoring and exercise stress testing is an indicator of risk for SCD. [The SCIa indicates that this paper has ...
... 400,000 lives annually in the US. If they are to be saved, the victims need to be identified prior to the fatal event. The presenceof certain types of ventricular extrasystoles exposed by monitoring and exercise stress testing is an indicator of risk for SCD. [The SCIa indicates that this paper has ...
CHF (Handout, B. Shah, 2005)
... hepatic congestion. Thyroid function as hypothyroidism and thyrotoxicosis can present as heat failure. BNP is a substance released in response to high ventricular filling and elevated values have been shown to coorelate with CHF. N Engl J Med 2002 Jul 18;347(3):161-7. ECG- Although any new finding f ...
... hepatic congestion. Thyroid function as hypothyroidism and thyrotoxicosis can present as heat failure. BNP is a substance released in response to high ventricular filling and elevated values have been shown to coorelate with CHF. N Engl J Med 2002 Jul 18;347(3):161-7. ECG- Although any new finding f ...
Define the different properties of cardiac muscles
... IMPORTANCE OF REFRACTORY PERIOD • Long refractory period prevents tetanic contractions • systole and diastole occur alternately. • It is very important for pumping blood to arteries. ...
... IMPORTANCE OF REFRACTORY PERIOD • Long refractory period prevents tetanic contractions • systole and diastole occur alternately. • It is very important for pumping blood to arteries. ...
pdf - Choosing Wisely
... patients unlikely to survive at least one year due to non-cardiac comorbidity. Because the explicit goal of primary prevention of sudden death with an ICD is the prevention of death due to life-threatening ventricular arrhythmias in patients with an otherwise reasonable expectation of survival, curr ...
... patients unlikely to survive at least one year due to non-cardiac comorbidity. Because the explicit goal of primary prevention of sudden death with an ICD is the prevention of death due to life-threatening ventricular arrhythmias in patients with an otherwise reasonable expectation of survival, curr ...
Ch 20 – The Heart
... a. spread impulse through ventricle b. cause muscle cells to contact *See plate 51 ...
... a. spread impulse through ventricle b. cause muscle cells to contact *See plate 51 ...
Drugs Used in Heart Failure
... Patients with cardiac disease resulting in slight limitation of physical activity. They are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain. ...
... Patients with cardiac disease resulting in slight limitation of physical activity. They are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain. ...
Cardiac resynchronisation therapy
... Your doctor is likely to suggest you have a number of tests before the decision is taken to implant a CRT device. You may have an angiogram (cardiac catheter) to check the blood supply to the heart. Due to a blockage or narrowing in one of the coronary arteries (vessels that supply the heart muscle ...
... Your doctor is likely to suggest you have a number of tests before the decision is taken to implant a CRT device. You may have an angiogram (cardiac catheter) to check the blood supply to the heart. Due to a blockage or narrowing in one of the coronary arteries (vessels that supply the heart muscle ...
international leaders in transforming heart disease
... A pioneer in electrophysiology, Dr. Moss worked with Dr. Klein in the late 1980s on device trials for the implantable cardioverter defibrillator (ICD), a device that shocks the heart back into normal rhythm in patients who have potentially deadly arrhythmias. The ICD replaced drug therapies that had ...
... A pioneer in electrophysiology, Dr. Moss worked with Dr. Klein in the late 1980s on device trials for the implantable cardioverter defibrillator (ICD), a device that shocks the heart back into normal rhythm in patients who have potentially deadly arrhythmias. The ICD replaced drug therapies that had ...
summary / samenVattInG Louis BW.indd 125 06-05-10 11:21
... remodeling of the pulmonary vasculature, resulting in increased pulmonary vascular resistance and right ventricular (RV) afterload. This leads to extensive RV remodeling and ultimately to right heart failure. Unfortunately, no definite cure exists. Nevertheless, in the last decade several new drugs ...
... remodeling of the pulmonary vasculature, resulting in increased pulmonary vascular resistance and right ventricular (RV) afterload. This leads to extensive RV remodeling and ultimately to right heart failure. Unfortunately, no definite cure exists. Nevertheless, in the last decade several new drugs ...
Cardiac contractility modulation
.jpg?width=300)
Cardiac contractility modulation (CCM) is a treatment for patients with moderate to severe left ventricular systolic heart failure (NYHA class II–IV). The short- and long-term use of this therapy enhances both the strength of ventricular contraction and the heart’s pumping capacity. The CCM mechanism is based on stimulation of the cardiac muscle by non-excitatory electrical signals (NES). CCM treatment is delivered by a pacemaker-like device that applies the NES, adjusted to and synchronized with the electrical action in the cardiac cycle.In CCM therapy, electrical stimulation is applied to the cardiac muscle during the absolute refractory period. In this phase of the cardiac cycle, electrical signals cannot trigger new cardiac muscle contractions, hence this type of stimulation is known as a non-excitatory stimulation. However, the electrical CCM signals increase the influx of calcium ions into the cardiac muscle cells (cardiomyocytes). In contrast to other electrical stimulation treatments for heart failure, such as pacemaker therapy or implantable cardioverter defibrillators (ICD), CCM does not affect the cardiac rhythm directly. Rather, the aim is to enhance the heart’s natural contraction (the native cardiac contractility) sustainably over long periods of time. Furthermore, unlike most interventions that increase cardiac contractility, CCM is not associated with an unfavorable increase in oxygen demand by the heart (measured in terms of Myocardial Oxygen Consumption or MVO2). This may be explained by the beneficial effect CCM has in improving cardiac efficiency. A meta-analysis in 2014 and an overview of device-based treatment options in heart failure in 2013 concluded that CCM treatment is safe, that it is generally beneficial to patients and that CCM treatment increases the exercise tolerance (ET) and quality of life (QoL) of patients. Furthermore, preliminary long-term survival data shows that CCM is associated with lower long-term mortality in heart failure patients when compared with expected rates among similar patients not treated with CCM.